Transforming Growth Factor Alpha (TGF-α) and Other Targets of Tumor Necrosis Factor-Alpha Converting Enzyme (TACE) in Murine Polycystic Kidney Disease
Open Access
- 1 May 2005
- journal article
- Published by Springer Science and Business Media LLC in Pediatric Research
- Vol. 57 (5 Part 1), 732-737
- https://doi.org/10.1203/01.pdr.0000159513.51898.60
Abstract
Transforming growth factor-alpha (TGF-α) is abnormally expressed in autosomal recessive polycystic kidney disease (ARPKD). Tumor necrosis factor-alpha converting enzyme (TACE), a metalloproteinase, mediates TGF-α processing. In this study, we sought to determine whether TGF-α was an absolute requirement for renal cystogenesis and whether its absence would modulate disease severity or related growth factors/receptors expression. Bpk heterozygotes were bred with TGF-α null mice to produce cystic and noncystic offspring with or without TGF-α. Assessments included kidney weight (KW), body weight (BW), blood urea nitrogen (BUN), and kidney and liver immunohistology. Western analysis assessed kidney expression of amphiregulin (AR), epidermal growth factor (EGF), heparin-binding EGF (HB-EGF), and their receptors, EGFR and ErbB4. A PCR-based methodology for genotyping bpk mice was also developed. No significant differences in KW, BW, KW/BW%, or BUN were seen in cystic mice with versus without TGF-α. Cystic kidney disease and liver disease histology were similar. AR, EGF, HB-EGF, EGFR, and ErbB4 were abnormally expressed to an equal degree in kidneys of mice with versus without TGF-α. Although previous data suggest a critical role of TGF-α in murine PKD, these data show that TGF-α is not required for renal cyst formation or kidney or liver disease progression. We speculate that the therapeutic effect of WTACE2 could have been due to effects on several TACE targets, including TGF-α, AR, and ErbB4, as well as metalloproteinases other than TACE.Keywords
This publication has 43 references indexed in Scilit:
- EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD ratsKidney International, 2003
- Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailabilityKidney International, 2003
- A novel inhibitor of tumor necrosis factor-α converting enzyme ameliorates polycystic kidney diseaseKidney International, 2001
- Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk micePediatric Nephrology, 2001
- Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitorKidney International, 2000
- An Essential Role for Ectodomain Shedding in Mammalian DevelopmentScience, 1998
- Epidermal growth factor receptor expression is abnormal in murine polycystic kidneyKidney International, 1995
- Hereditary Error in Epidermal Growth Factor Prohormone Metabolism in a Rat Model of Autosomal Dominant Polycystic Kidney DiseaseBiochemical and Biophysical Research Communications, 1993
- An Inborn Error in Epidermal Growth Factor Prohormone Metabolism in a Mouse Model of Autosomal Recessive Polycystic Kidney DiseaseBiochemical and Biophysical Research Communications, 1993
- Defective epidermal growth factor gene expression in mice with polycystic kidney diseaseDevelopmental Biology, 1990